Hypera SA
BOVESPA:HYPE3

Watchlist Manager
Hypera SA Logo
Hypera SA
BOVESPA:HYPE3
Watchlist
Price: 26.4 BRL 0.34% Market Closed
Market Cap: 16.7B BRL

EV/EBIT
Enterprise Value to EBIT

23.8
Current
11.9
Median
16.3
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
23.8
=
Enterprise Value
22.5B BRL
/
EBIT
947.3m BRL
Market Cap EV/EBIT
BR
Hypera SA
BOVESPA:HYPE3
16.7B BRL 23.8
US
Eli Lilly and Co
NYSE:LLY
725.7B USD 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
369.6B USD 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 16
CH
Roche Holding AG
SIX:ROG
212.9B CHF 11.3
CH
Novartis AG
SIX:NOVN
189.4B CHF 14.2
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP 197.6
US
Merck & Co Inc
NYSE:MRK
195.3B USD 10.2
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
US
Pfizer Inc
NYSE:PFE
131.4B USD 10.2
EBIT Growth EV/EBIT to Growth
BR
Hypera SA
BOVESPA:HYPE3
Average EV/EBIT: 1 699.6
23.8
24%
1
US
Eli Lilly and Co
NYSE:LLY
38.4
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
16
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.3
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.6
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.2
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
11.4
2-Years Forward
EV/EBIT
7.8
3-Years Forward
EV/EBIT
6.9